Searching News Database: EDEMA4
HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
HSMN NewsFeed - 31 Oct 2007
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development Officer
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development Officer
HSMN NewsFeed - 14 May 2007
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
HSMN NewsFeed - 4 May 2007
Dyax Announces the Resignation of Thomas Beck, M.D., President and Chief Operating Officer
Dyax Announces the Resignation of Thomas Beck, M.D., President and Chief Operating Officer
HSMN NewsFeed - 26 Apr 2007
Dyax Announces the Appointment of Gustav Christensen as Executive Vice President and Chief Business Officer
Dyax Announces the Appointment of Gustav Christensen as Executive Vice President and Chief Business Officer
HSMN NewsFeed - 17 Apr 2007
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
HSMN NewsFeed - 12 Apr 2007
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!